Before testing whether this modified toxin would be effective in canine and human OSA cell lines, we first examined the MMP, uPA, and MT1-MMP expression in canine (D17) and human (MG63) OSA by immunofluorescence assay. This evidence concerns the gene PLAU and obstructive sleep apnea syndrome.